ARQT Arcutis Biotherapeutics Inc
1,889
$9.48
$0.13
(1.39%)
| Watchers | 1,889 |
| 52-Wk Low | $1.76 |
| 52-Wk High | $13.17 |
| Market Cap | $1.1B |
| Volume | 1,280.00 |
| 52-Wk High | $13.17 |
| 52-Wk Low | $1.76 |
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving PremarketBenzinga • 7 days ago
read more...
Share to Feed
US Futures Coiled Tightly Ahead Of Key CPI Print
Equity futures were set to hold yesterday's gains ahead of today's CPI report, but will move violently either higher or lower after...
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.
read more...
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) dropped 6.2% during mid-day trading on Monday . The stock traded as low as $9.16 and last traded at $9.30. Approximately...
Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments...
WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNS Research Report), Arcutis Biotherapeutics...
Deutsche Bank AG lifted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT Free Report) by 13.7% in the third quarter, according to the company in its most recent filing with the...
This indicator may be signaling that ARQT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...